Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

Oncogene. 2021 Feb;40(8):1393-1395. doi: 10.1038/s41388-020-01611-6. Epub 2021 Jan 26.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors
  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / immunology*
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / immunology
  • Humans
  • Immune Checkpoint Inhibitors / immunology
  • Immune Checkpoint Inhibitors / therapeutic use*
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Neoplasms / therapy*

Substances

  • Antibodies, Monoclonal
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors